ICAM1 and inflammatory bowel disease: Leukocyte trafficking has been identified as a specific target for the treatment of IBD and is a multi-step procedure involving integrins on leukocytes and their immunoglobulin superfamily counterparts as ligands, such as ICAM-1 (Rivera-Nieves et al., 2008; Mosli et al., 2014).